We are thrilled to announce that we held our first meeting yesterday with the University of Pennsylvania, marking the commencement of an inspiring collaboration. Our teams are eager to dedicate their expertise towards a crucial R01 project: “Optimizing theranostic radiopharmaceutical therapy to combat resistance to PARP inhibition in advanced ovarian cancer.” This collaboration is a significant stride forward in pursuing novel therapies for ovarian cancer, and we are ready to pioneer new frontiers in medical research. At the core of our R01 project is the potent approach of alpha-targeted therapy for ovarian cancer. This promising and innovative technique aims to enhance the treatment efficacy for patients with advanced disease stages. This therapy can potentially change the landscape of ovarian cancer treatment significantly by improving patient outcomes and quality of life.
We will analyze the experiments performed at the University of Pennsylvania, aiming to contribute to this advanced research initiative actively and constructively. We are committed to predicting and aiding the design of innovative new experiments by means of modeling and dosimetric calculations using our tools for microdosimetry, DNA damage, and DNA repair. These experiments are designed to assess the effectiveness of theranostic radiopharmaceutical therapies rigorously. Through this active contribution, we hope to pave the way for more effective treatment modalities in the coming years.
We look forward to the next five years, filled with intense research and discovery. We are excited to see where our combined efforts will lead us, and hopeful for the possibilities this collaboration could uncover.